We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Brian Baumann

Brian Baumann MD

Radiation Oncology Resident Physician, Hospital of the University of Pennsylvania

Dr. Brian Baumann is a radiation oncology resident physician at the Hospital of the University of Pennsylvania.  He received his bachelor’s degree from Princeton University and his medical degree from the University of Pennsylvania School of Medicine.  His research interests include genitourinary cancers, with a particular emphasis on urothelial cell carcinoma and the role of adjuvant radiation therapy after radical cystectomy.  His research helped to demonstrate the significant problem of local-regional failure after radical cystectomy for patients with ≥pT3 disease even with modern surgical techniques.  He developed and published an externally validated risk stratification model to identify patients who are at highest risk for local-regional failure and who are most likely to benefit from adjuvant radiation.  He also determined the patterns of failure in the pelvis following cystectomy to inform the design of radiation portals and performed a dosimetric analysis of IMRT vs. 3-D conformal radiation therapy for adjuvant radiation that reported on the superiority of IMRT to achieve significantly lower bowel and rectal doses.  He led an effort to develop an international, multidisciplinary consensus contouring guide for adjuvant radiation therapy.  His research provided much of the groundwork for the newly opened NRG-GU001 trial of adjuvant IMRT vs. observation for patients at high-risk of local failure after cystectomy.